The stock's fall snapped a four-day winning streak.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50 ...

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep correction. Lilly is by no means in bad shape, but because the stock's ...

Eli Lilly (NYSE:LLY) is setting the stage for a strong 2025, with its fourth-quarter results and forward guidance reflecting solid momentum. The company's adjusted earnings per share are expected ...

Investors in Eli Lilly (Symbol: LLY) saw new options begin trading today, for the March 2026 expiration. One of the key data points that goes into the price an option buyer is willing to pay ...

Eli Lilly exceeded analyst forecasts for both sales and earnings in Q4 2024. As has been true for a while, sales of GLP-1 drugs Mounjaro and Zepbound drove both sales and earnings growth.

Shares of Eli Lilly & Co. dropped over 7% on Tuesday morning ... bullish,’ with the ticker climbing to the top five trending symbols list amid a spike in message volume. Many retail investors ...

At Holdings Channel, we have reviewed the latest batch of the 31 most recent 13F filings for the 12/31/2024 reporting period, and noticed that Eli Lilly (Symbol: LLY) was held by 22 of these funds.

Eli Lilly and Company (NYSE:LLY) today announced the opening of the Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport dedicated to... Analysts at ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

View Eli Lilly and Company (LLY) current and estimated P/E ratio data provided by Seeking Alpha.